Cabergoline to prevent lactation and ease breast symptoms after abortion or pregnancy loss
Official title: Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms After 12-18 Week Abortion or Pregnancy Loss: A Pilot and Randomized Controlled Trial
Run by Maimonides Medical Center · NCT07492160 · Data updated 2026-11-12
This trial will test whether a single 1 mg oral dose of cabergoline can prevent lactation and reduce breast symptoms in people aged 18 and older having an abortion or pregnancy loss at 12–18 weeks.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 348 (estimated) |
| Sponsor | Maimonides Medical Center Academic / other |
| Locations | 1 site (Brooklyn, New York) |
| Status | Recruiting |
| Started | March 16, 2026 |
| Main results expected | February 2028 |
| Study ends | April 2028 |
| Registry record updated | September 17, 2026 |
| Trial ID | NCT07492160 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People aged 18 or older with a pregnancy of 12–18 weeks who are undergoing treatment for induced abortion or spontaneous pregnancy loss at Maimonides Medical Center and can give informed consent and complete surveys.
✕Probably not a fit
People who are currently breastfeeding, have had a mastectomy, are taking dopamine agonists or antagonists, have contraindications to cabergoline, or whose pregnancy is outside 12–18 weeks are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, placebo-controlled Phase 2 study gives participants a single 1 mg oral dose of cabergoline or matching placebo around the time of a planned abortion or treatment for pregnancy loss. Participants complete a baseline survey of breast symptoms before the procedure and follow-up surveys to measure whether they develop engorgement, milk leakage, tenderness, or need for pain relief. The main outcomes are the proportion of participants with breast symptoms and the severity and bother of those symptoms compared between cabergoline and placebo groups. The trial is conducted at Maimonides Medical Center and enrolls adults 18 years and older with gestational ages between 12 and 18 weeks.
Why it matters
Potential benefit: If effective, cabergoline could prevent lactation and reduce physical and emotional discomfort from breast symptoms after early second-trimester abortion or pregnancy loss.
How similar studies have gone: Cabergoline is known to suppress lactation after full-term delivery and small studies suggest benefit for later second-trimester loss, but evidence is limited for use specifically at 12–18 weeks.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pregnant people aged 18 years or older * Gestational age between 12 and 18 weeks * Undergoing treatment for spontaneous or induced abortion at Maimonides Medical Center * Able to provide informed consent * Willing and able to complete study surveys Exclusion Criteria: * Prior mastectomy * Currently breastfeeding * Current use of a dopamine agonist or dopamine antagonist medication * Known contraindication to Cabergoline according to the medication prescribing information
Where it's running
-
Maimonides Medical Center
Brooklyn, New York, United States Recruiting
Study contacts
- Principal investigator: June Ng, MD — Maimonides Medical Canter
- Study coordinator: June Ng, MD
- Email: JuNg@maimo.org
- Phone: 718-283-7048
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pregnant Women Living with HIV on Bictegravir/Emtricitabine/Tenofovir Alafenamide
This study looks at how B/F/TAF is used in pregnant women with HIV and whether it helps maintain viral suppression from before conception through delivery.
-
Pelvic Floor Training and a Modified Lumbopelvic Belt for Symphysis Pubis Pain in Pregnancy
This study tests whether pelvic floor muscle training plus a modified lumbopelvic belt can reduce pain and improve function for pregnant women with symphysis pubis pain.
-
Effective Communication in VBAC Counseling
This study tests how clearly doctors and midwives explain VBAC options during prenatal visits and whether patients feel understood.
-
Innovative Multidisciplinary and Virtual Care for IBD in Pregnancy
This study tests a dedicated IBD pregnancy care model, including a new virtual approach, to see if it improves access and quality of care for pregnant people with Crohn's disease or ulcerative colitis.
-
Compare spinal-epidural versus general anesthesia for babies after cesarean delivery
This trial tests whether the type of anesthesia used for cesarean delivery affects newborn hearing in babies.
-
Pregnant women weight-management support via an app and care model
Aims to try a smartphone-based weight-management program plus professional support for pregnant women to see if it helps manage gestational weight and promote healthy behaviors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.